Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-22. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== Overdose == An overdose of modafinil can lead to a range of symptoms and complications. Psychiatric symptoms may include psychosis, mania, hallucinations, and suicidal ideation, which can occur even in individuals without a history of mental illness and may persist after discontinuation of modafinil. Neurological complications, such as seizures, tremors, dystonia (involuntary muscle contractions), and dyskinesia (uncontrolled movements), may arise from modafinil's interaction with various neurotransmitter systems. Allergic reactions such as rash, angioedema (swelling beneath the skin), anaphylaxis (a severe whole-body allergic reaction), and Stevens–Johnson syndrome (a serious skin and mucous membrane disorder) may rarely be triggered by an immunological response to modafinil or its metabolites. Cardiovascular complications like hypertension, tachycardia (rapid heart rate), chest pain, and arrhythmias may also occur because modafinil stimulates the sympathetic nervous system. In animal studies, the median lethal dose (LD50) of modafinil varies among species and depends on the route of administration. In mice and rats, the LD50 is approximately 1250 mg/kg if administered via an injection, but the oral LD50 for rats is 3400 mg/kg. The LD50 value for humans have not been established. Human clinical trials have involved total daily doses up to 1200 mg/d for 7–21 days. Acute one-time total overdoses up to 4500 mg have not been life-threatening but resulted in symptoms like agitation, insomnia, tremor, palpitations, and gastrointestinal disturbances.
=== 18 January === Forty people were killed in an RSF attack on the village of Jebel Hilla in North Darfur. Six drones struck the Al-Shawak power station in Gedaref State, injuring civil defence personnel and causing blackouts across the state and in Kassala State. Other drones hit the Gedaref state water station while another crashed near a bus station along the Gedaref-Kassala-Port Sudan highway. The SAF reached the Al-Shukri junction in Shambat, Khartoum Bahri, while the RSF retreated by one kilometer southwards to the Hassan Ibrahim Malik University City. At least three people were killed by RSF shelling in Omdurman. The RSF claimed to have taken Al-Hallaf, Drishaqi and Mao in North Darfur.
===== Supplemental Offer and Acceptance Program ===== The Supplemental Offer and Acceptance Program (SOAP) is a process for partially matched and fully unmatched applicant through the Match. Previous to the creation of SOAP, applicants were given the opportunity to contact the programs about the open positions in a process informally called "the scramble". This frantic, loosely structured system forced soon-to-be medical school graduates to choose within minutes programs not on their original Match list. In 2012, the NRMP introduced the organized system called SOAP. As part of the transition, Match Day was also moved from the third Thursday in March to the third Friday. The SOAP occurs during Match Week. First the applicants eligible for SOAP, are informed they did not secure a Match position on the Monday of Match Week. The locations of remaining unfilled residency positions are released to the unmatched applicants the following day. Then programs contact applicants for interviews that usually occur via phone calls. After that, programs prepare lists of applicants and the positions open are offered by each program one at a time to the top applicant on their list. The applicant may accept the offer or reject it. If the offer is rejected it will go to the next applicant in the program list during the next round of SOAP. During Match year 2021 there were four rounds of SOAP.
==== Addiction ==== Drug addiction is a complex set of behaviors typically associated with misuse of certain drugs, developing over time and with higher drug dosages. Addiction includes psychological compulsion, to the extent that the affected person persists in actions leading to dangerous or unhealthy outcomes. Opioid addiction includes insufflation or injection, rather than taking opioids orally as prescribed for medical reasons. In European nations such as Austria, Bulgaria, and Slovakia, slow-release oral morphine formulations are used in opiate substitution therapy (OST) for patients who do not well tolerate the side effects of buprenorphine or methadone. Buprenorphine can also be used together with naloxone for a longer treatment of addiction. In other European countries including the UK, this is also legally used for OST although on a varying scale of acceptance. Slow-release formulations of medications are intended to curb misuse and lower addiction rates while trying to still provide legitimate pain relief and ease of use to pain patients. Questions remain, however, about the efficacy and safety of these types of preparations. Further tamper resistant medications are currently under consideration with trials for market approval by the FDA. The amount of evidence available only permits making a weak conclusion, but it suggests that a physician properly managing opioid use in patients with no history of substance use disorder can give long-term pain relief with little risk of developing addiction, or other serious side effects.
Sources: en.wikipedia.org
16 April – Scientists at the Riken institute demonstrate "advanced dual-chirped optical parametric amplification", which provides a 50-fold increase in the energy of single-cycle laser pulses. This new technique may advance the development of attosecond lasers. 23 April – The world's largest 3D printer, dubbed Factory of the Future 1.0 (FoF 1.0), is presented by the University of Maine. Using thermoplastic polymers, the machine can print objects as large as 96 feet (29 m) long by 32 feet (9.8 m) wide by 18 feet (5.5 m) high, at a rate of 500 pounds (230 kg) per hour. 24 April – Demonstration of synthetic diamond created at 1 atmosphere of pressure in around 150 minutes without needing seeds. 25 April – The first meta-analysis of 665 trials of conservation action such as invasive species control measuring biodiversity is published. 26 April – mRNA-4157/V940, the first personalised melanoma vaccine based on mRNA, enters a final-stage Phase III trial. 29 April Timothy A. Coleman, with the University of Alabama in Huntsville, Richard L. Thompson with the NOAA Storm Prediction Center, and Dr. Gregory S. Forbes, a retired meteorologist from The Weather Channel publish an article to the Journal of Applied Meteorology and Climatology stating, "it is apparent that the perceived shift in tornado activity from the traditional tornado alley in the Great Plains to the eastern U.S. is indeed real". Physicists outline how a subluminal warp drive that does not require exotic negative energy may be possible.
Lead poisoning (Pb), in contrast to arsenic poisoning, is caused by industrial materials, such as leaded gasoline and lead leached from plumbing. Use of leaded gasoline has declined precipitously since the 1970s. Lead (from lead(II) azide or lead styphnate used in firearms) gradually accumulates at firearms training grounds, contaminating the local environment and exposing range employees to a risk of lead poisoning. Beryllium poisoning (Be) is attributed to the ability of Be2+ to replace Mg2+ in some enzymes. Be has been classified by one agency as a carcinogen. Cadmium poisoning (Cd) came into focus with the discovery of itai-itai disease due to cadmium-contaminated waters resulting from mining in the Toyama Prefecture starting around 1912. The term refers to the severe pains (Japanese: 痛い, romanized: itai) people with the condition felt in the spine and joints. Cd2+ is thought to accumulate in the kidneys, where it tightly binds to the sulfur in cysteine-containing proteins. Cadmium is also present as a material used in many electronic devices, thus it can leach into groundwater after being disposed of into landfills of electronic waste. Chromium poisoning (Cr) is primarily due to hexavalent chromium, Cr+6, creating as a side effect of industrial processes. While hexavalent chromium is a known human carcinogen, and it has become widespread in the environment, the impact of environmental contamination with this element are not known. Mercury poisoning (Hg) came into sharp focus with the discovery of Minamata disease, named for the Japanese city of Minamata.
Dermatological/integumental: oily skin, acne vulgaris, acne conglobata, seborrhea, stretch marks (due to rapid muscle enlargement), hypertrichosis (excessive body hair growth), androgenic alopecia (pattern hair loss; scalp baldness), fluid retention/edema. Reproductive/endocrine: libido changes, reversible infertility, hypogonadotropic hypogonadism. Male-specific: spontaneous erections, nocturnal emissions, priapism, erectile dysfunction, gynecomastia (mostly only with aromatizable and hence estrogenic AAS), oligospermia/azoospermia, testicular atrophy, intratesticular leiomyosarcoma, prostate hypertrophy, prostate cancer. Female-specific: masculinization, irreversible voice deepening, hirsutism (excessive facial/body hair growth), menstrual disturbances (e.g., anovulation, oligomenorrhea, amenorrhea, dysmenorrhea), clitoral enlargement, breast atrophy, uterine atrophy, teratogenicity (in female fetuses). Child-specific: premature epiphyseal closure and associated short stature, precocious puberty in boys, delayed puberty and contrasexual precocity in girls. Psychiatric/neurological: mood swings, irritability, aggression, violent behavior, impulsivity/recklessness, hypomania/mania, euphoria, depression, anxiety, dysphoria, suicidality, delusions, psychosis, withdrawal, dependence, neurotoxicity, cognitive impairment. Musculoskeletal: muscle hypertrophy, muscle strains, tendon ruptures, rhabdomyolysis.
Sources: en.wikipedia.org
Military advice from the era also suggests plundering seized enemy storehouses and granaries to provision an army. The Aztecs timed their war seasons to begin just after the harvest. Armies would be equipped with foodstuffs such as toasted tortillas, beans, chilies, dried meats such as venison, turkey, and peccary, and cacao paste. Armies on campaign brought along young cadet soldiers who acted as porters, carrying up to 50 pounds (23 kg) of supplies and equipment each. Soldiers heading off on campaign would receive contributions from their families and communities. While on the move, armies collected food from tributary cities. Messengers were sent ahead of an approaching army to demand stockpiled tribute. Refusal to contribute was seen as an act of rebellion. The Inca Empire ensured that its armies could frequently be resupplied while on the move. Inca armies moved along an extensive road system dotted with waystations that ensured troops did not have to march more than 20 kilometers without being resupplied. Their supplies were carried by llamas as well as porters. Food and weapons were stockpiled in storehouses called qullqa that dotted the countryside, which armies could draw upon as they moved. The Incas strictly prohibited their soldiers from looting local communities, punishing such offenses with execution. The food eaten by soldiers was largely the same as that consumed by the civilian population in daily life, although they probably ate dehydrated food more frequently. Therefore, staples would have included corn, potatoes, and quinoa.
Reagent co-flow and droplet fusion methods are tied to droplet formation events which lack downstream flexibility. To decouple reagent addition from droplet creation, a setup where reagent stream flows through a channel perpendicular to the droplet stream is utilized. An injection droplet is then merged with the plug as it passes the channel. Reagent volume is controlled by the flow rate of the perpendicular reagent channel. An early challenge for such systems is that reagent droplet merging was not reproducible for stable emulsions. By adapting the use of an actuated electric field into this geometry, Abate et al. achieved sub-picoliter control of reagent injection. This approach, termed picoinjection, controls injection volume through reagent stream pressure and droplet velocity. Further work on this method has aimed to reduce pressure fluctuations that impede reproducible injections. Injection of the pressurized aqueous fluid occurs when the electrodes are activated creating an electric field that destabilizes the aqueous fluid/oil interface, triggering the injection. Key advantages of picoinjection include low inadvertent material transfer between droplets and maintenance of droplet compartmentalization through the injection, however, electrodes are often fabricated using metal-solder which can complicate construction of the microfluidic device through increased fabrication time as a result of a more intricate design.
=== Chemical fingerprinting and breath analysis === The exhaled human breath contains a few thousand volatile organic compounds and is used in breath biopsy and is used in breath biopsy as a biomarker to test for diseases, such as lung cancer. One study has shown that "volatile organic compounds ... are mainly blood borne and therefore enable monitoring of different processes in the body." And it appears that VOC compounds in the body "may be either produced by metabolic processes or inhaled/absorbed from exogenous sources" such as environmental tobacco smoke. Chemical fingerprinting and breath analysis of volatile organic compounds has also been demonstrated with chemical sensor arrays, which utilize pattern recognition for detection of component volatile organics in complex mixtures such as breath gas.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.